Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/20707Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Baltayiannis, G. | en |
| dc.contributor.author | Katsanos, K. | en |
| dc.contributor.author | Karayiannis, P. | en |
| dc.contributor.author | Tsianos, E. V. | en |
| dc.date.accessioned | 2015-11-24T19:09:29Z | - |
| dc.date.available | 2015-11-24T19:09:29Z | - |
| dc.identifier.issn | 0269-2813 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/20707 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adolescent | en |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Antiviral Agents/*therapeutic use | en |
| dc.subject | Female | en |
| dc.subject | Greece | en |
| dc.subject | Hepatitis B e Antigens | en |
| dc.subject | Hepatitis B, Chronic/*drug therapy | en |
| dc.subject | Humans | en |
| dc.subject | Interferon-alpha/*therapeutic use | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Prospective Studies | en |
| dc.subject | Recurrence | en |
| dc.subject | Survival Analysis | en |
| dc.subject | Treatment Outcome | en |
| dc.title | Interferon-alpha therapy in HBeAg-negative chronic hepatitis B: a long-term prospective study from north-western Greece | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1111/j.1365-2036.2006.03008.x | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/16886919 | - |
| heal.identifier.secondary | http://onlinelibrary.wiley.com/store/10.1111/j.1365-2036.2006.03008.x/asset/j.1365-2036.2006.03008.x.pdf?v=1&t=h0uldm7g&s=b01af0fb4f0e9890d991b587d10c864d86636f7b | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2006 | - |
| heal.abstract | AIMS: To determine the long-term response to interferon-alpha therapy in patients with hepatitis B e antigen-negative chronic hepatitis B, and the factors independently associated with response and survival. METHODS: Sixty-three patients with documented hepatitis B e antigen-negative chronic hepatitis B treated with interferon-alpha for a year were followed-up for a period of 6 years. RESULTS: Sustained biochemical and virological response was seen in 34.91% and 33.33% of patients at 6 and 12 months of follow-up, respectively, and histological improvement in 54.5% of sustained responders compared with non-responders (7.1%, P = 0.004, chi-squared test), at 6 months of follow-up. Multivariate analysis showed that patients with hepatitis B virus-DNA levels at 6 months of treatment <10,000 copies/mL had a low probability of relapse, compared with those with levels >10 000 copies/mL (P = 0.032). Age (>65 years) and hepatitis B virus-DNA level at 6 months of treatment (>10,000 copies/mL) were the independent factors for disease progression and survival (P = 0.041 and P = 0.044 respectively). At 6 years, a sustained response was still present in 19.04% of patients and 4.8% of them had developed anti-HBs. CONCLUSION: Hepatitis B virus-DNA monitoring by quantitative polymerase chain reaction at 6 months of treatment may allow for early prediction of response to interferon-alpha, and may serve as an indicator of disease progression in the future. | en |
| heal.journalName | Aliment Pharmacol Ther | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Baltayiannis-2006-Interferon-alpha the.pdf | 140.94 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
